• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Keloids - Pipeline Review, H2 2012 Product Image

Keloids - Pipeline Review, H2 2012

  • ID: 2366388
  • December 2012
  • 32 pages
  • Global Markets Direct

Keloids – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Keloids - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Keloids, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Keloids. Keloids - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Keloids.
- A review of the Keloids products under development by companies and universities/research institutes based on information derived from company and industry-specific READ MORE >

2
List of Tables 4
List of Figures 4
Introduction 5
REPORT COVERAGE 5
Keloids Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Keloids 7
Keloids Therapeutics under Development by Companies 9
Keloids Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 11
Comparative Analysis 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Pre-Clinical Stage Products 13
Comparative Analysis 13
Keloids Therapeutics – Products under Development by Companies 14
Keloids Therapeutics – Products under Investigation by Universities/Institutes 15
Companies Involved in Keloids Therapeutics Development 16
Keloids – Therapeutics Assessment 16
Assessment by Monotherapy Products 16
Assessment by Combination Products 17
Assessment by Route of Administration 18
Assessment by Molecule Type 20
Drug Profiles 22
Fucicort - Drug Profile 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
Fucicort - Drug Profile 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
bevacizumab - Drug Profile 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
sorafenib tosylate - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
interferon alfa-2b + interferon gamma-1b - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
psoriasin - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
koebnerisin - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Keloids Therapeutics – Discontinued Products 29
Keloids – Product Development Milestones 30
Featured News & Press Releases 30
Mar 03, 2010: Capstone To Continue AZX100 Phase II Clinical Trial In Keloid Scarring 30
Appendix 31
Methodology 31
Coverage 31
Secondary Research 31
Primary Research 31
Expert Panel Validation 31
Contact Us 32
Disclaimer 32

List of Tables
Number of Products Under Development for Keloids, H2 2012 7
Products under Development for Keloids – Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Number of Products under Investigation by Universities/Institutes, H2 2012 10
Comparative Analysis by Late Stage Development, H2 2012 11
Comparative Analysis by Mid Clinical Stage Development, H2 2012 12
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 13
Products under Development by Companies, H2 2012 14
Products under Investigation by Universities/Institutes, H2 2012 15
Assessment by Monotherapy Products, H2 2012 16
Assessment by Combination Products, H2 2012 17
Assessment by Stage and Route of Administration, H2 2012 19
Assessment by Stage and Molecule Type, H2 2012 21
Keloids Therapeutics – Discontinued Products 29

List of Figures
Number of Products under Development for Keloids, H2 2012 7
Products under Development for Keloids – Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Products under Investigation by Universities/Institutes, H2 2012 10
Late Stage Products, H2 2012 11
Mid Clinical Stage Products, H2 2012 12
Pre-Clinical Stage Products, H2 2012 13
Assessment by Monotherapy Products, H2 2012 16
Assessment by Combination Products, H2 2012 17
Assessment by Route of Administration, H2 2012 18
Assessment by Stage and Route of Administration, H2 2012 19
Assessment by Molecule Type, H2 2012 20
Assessment by Stage and Molecule Type, H2 2012 21

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos